ADMA Biologics, Inc. (ADMA)

NASDAQ: ADMA · IEX Real-Time Price · USD
5.40
+0.14 (2.66%)
At close: Feb 26, 2024, 4:00 PM
5.44
+0.04 (0.74%)
After-hours: Feb 26, 2024, 7:50 PM EST
2.66%
Market Cap 1.22B
Revenue (ttm) 234.29M
Net Income (ttm) -22.83M
Shares Out 225.97M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE 29.83
Dividend n/a
Ex-Dividend Date n/a
Volume 1,950,533
Open 5.25
Previous Close 5.26
Day's Range 5.21 - 5.44
52-Week Range 2.95 - 5.46
Beta 0.47
Analysts Strong Buy
Price Target 6.75 (+25.0%)
Earnings Date Feb 28, 2024

About ADMA

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposur... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 617
Stock Exchange NASDAQ
Ticker Symbol ADMA
Full Company Profile

Financial Performance

In 2022, ADMA Biologics's revenue was $154.08 million, an increase of 90.36% compared to the previous year's $80.94 million. Losses were -$65.90 million, -8.02% less than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ADMA stock is "Strong Buy." The 12-month stock price forecast is $6.75, which is an increase of 25.00% from the latest price.

Price Target
$6.75
(25.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics' New Capabilities for the First Time to Automate and Realize Efficiency Im...

5 days ago - GlobeNewsWire

ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Millio...

7 weeks ago - GlobeNewsWire

ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management

New $135 Million Credit Facility Replaces Existing $159 Million Credit Facility, a 15% Decrease in Total Debt Further Supports Rapid Q-o-Q and Y-o-Y Earnings Accretion RAMSEY, N.J. and BOCA RATON, Fla...

2 months ago - GlobeNewsWire

ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older

Signifies the Successful Fulfillment of BIVIGAM's Post Marketing Commitments as Part of the Original BLA Approval

2 months ago - GlobeNewsWire

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficiency FDA Approval Signifies the Accomplishment of ADMA's Corporate Goal of Plasma Supply Self-Sufficienc...

3 months ago - GlobeNewsWire

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update

3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to...

3 months ago - GlobeNewsWire

ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023

RAMSEY, N.J. and BOCA RATON, Fla.

4 months ago - GlobeNewsWire

ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement ...

7 months ago - GlobeNewsWire

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

RAMSEY, N.J. and BOCA RATON, Fla.

7 months ago - GlobeNewsWire

ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY...

7 months ago - GlobeNewsWire

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1) , Totaling $2.5 Million,...

10 months ago - GlobeNewsWire

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

RAMSEY, N.J. and BOCA RATON, Fla.

10 months ago - GlobeNewsWire

ADMA Biologics Announces Amendment to Credit Agreement

Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, F...

10 months ago - GlobeNewsWire

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase

1 year ago - GlobeNewsWire

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET

1 year ago - GlobeNewsWire

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

1 year ago - GlobeNewsWire

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase

1 year ago - GlobeNewsWire

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life

1 year ago - GlobeNewsWire

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...

1 year ago - GlobeNewsWire

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...

1 year ago - GlobeNewsWire

ADMA Biologics Announces Proposed Public Offering of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manu...

1 year ago - GlobeNewsWire

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million

1 year ago - GlobeNewsWire

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase

1 year ago - GlobeNewsWire

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

1 year ago - GlobeNewsWire